-
1
-
-
45749134564
-
The anticancer immune response: Indispensable for therapeutic success?
-
Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success? J Clin Invest 2008;118:1991-2001.
-
(2008)
J Clin Invest
, vol.118
, pp. 1991-2001
-
-
Zitvogel, L.1
Apetoh, L.2
Ghiringhelli, F.3
Andre, F.4
Tesniere, A.5
Kroemer, G.6
-
2
-
-
4644324025
-
Cancer immunotherapy: Moving beyond current vaccines
-
Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
-
(2004)
Nat Med
, vol.10
, pp. 909-915
-
-
Rosenberg, S.A.1
Yang, J.C.2
Restifo, N.P.3
-
3
-
-
77955534002
-
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity
-
Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010;18:160-70.
-
(2010)
Cancer Cell
, vol.18
, pp. 160-170
-
-
Park, S.1
Jiang, Z.2
Mortenson, E.D.3
Deng, L.4
Radkevich-Brown, O.5
Yang, X.6
-
5
-
-
84859893371
-
Histone methylation: A dynamic mark in health, disease and inheritance
-
Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet 2012;13:343-57.
-
(2012)
Nat Rev Genet
, vol.13
, pp. 343-357
-
-
Greer, E.L.1
Shi, Y.2
-
6
-
-
0036830642
-
Role of histone H3 lysine 27 methylation in Polycomb-group silencing
-
Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002;298:1039-43.
-
(2002)
Science
, vol.298
, pp. 1039-1043
-
-
Cao, R.1
Wang, L.2
Wang, H.3
Xia, L.4
Erdjument-Bromage, H.5
Tempst, P.6
-
7
-
-
78751662908
-
The Polycomb complex PRC2 and its mark in life
-
Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature 2011;469:343-9.
-
(2011)
Nature
, vol.469
, pp. 343-349
-
-
Margueron, R.1
Reinberg, D.2
-
8
-
-
58149239686
-
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer
-
Varambally S, Cao Q,Mani RS, Shankar S,Wang X, Ateeq B, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008;322:1695-9.
-
(2008)
Science
, vol.322
, pp. 1695-1699
-
-
Varambally, S.1
Cao, Q.2
Mani, R.S.3
Shankar, S.4
Wang, X.5
Ateeq, B.6
-
9
-
-
17144412566
-
Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases
-
Mimori K, Ogawa K, Okamoto M, Sudo T, Inoue H, Mori M. Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases. Eur J Surg Oncol 2005;31:376-80.
-
(2005)
Eur J Surg Oncol
, vol.31
, pp. 376-380
-
-
Mimori, K.1
Ogawa, K.2
Okamoto, M.3
Sudo, T.4
Inoue, H.5
Mori, M.6
-
10
-
-
33846649587
-
Polycomb-mediated methylation on Lys27 of histone H3 premarks genes for de novo methylation in cancer
-
Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, et al. Polycomb-mediated methylation on Lys27 of histone H3 premarks genes for de novo methylation in cancer. Nat Genet 2007;39: 232-6.
-
(2007)
Nat Genet
, vol.39
, pp. 232-236
-
-
Schlesinger, Y.1
Straussman, R.2
Keshet, I.3
Farkash, S.4
Hecht, M.5
Zimmerman, J.6
-
12
-
-
84900459331
-
IL-22CD4 T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L
-
Kryczek I, Lin Y, Nagarsheth N, Peng D, Zhao L, Zhao E, et al. IL-22CD4 T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity 2014;40:772-84.
-
(2014)
Immunity
, vol.40
, pp. 772-784
-
-
Kryczek, I.1
Lin, Y.2
Nagarsheth, N.3
Peng, D.4
Zhao, L.5
Zhao, E.6
-
13
-
-
4644237613
-
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
-
Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
-
(2004)
Nat Med
, vol.10
, pp. 942-949
-
-
Curiel, T.J.1
Coukos, G.2
Zou, L.3
Alvarez, X.4
Cheng, P.5
Mottram, P.6
-
14
-
-
0038273853
-
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
-
Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003;9:562-7.
-
(2003)
Nat Med
, vol.9
, pp. 562-567
-
-
Curiel, T.J.1
Wei, S.2
Dong, H.3
Alvarez, X.4
Cheng, P.5
Mottram, P.6
-
15
-
-
84884354300
-
Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing micro-RNA101 and suppressing the corepressor CtBP2
-
Cui TX, Kryczek I, Zhao L, Zhao E, Kuick R, Roh MH, et al. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing micro-RNA101 and suppressing the corepressor CtBP2. Immunity 2013;39: 611-21.
-
(2013)
Immunity
, vol.39
, pp. 611-621
-
-
Cui, T.X.1
Kryczek, I.2
Zhao, L.3
Zhao, E.4
Kuick, R.5
Roh, M.H.6
-
16
-
-
84884692313
-
Inactivation of intergenic enhancers by EBNA3A initiates and maintains polycomb signatures across a chromatin domain encoding CXCL10 and CXCL9
-
Harth-Hertle ML, Scholz BA, Erhard F, Glaser LV, Dolken L, Zimmer R, et al. Inactivation of intergenic enhancers by EBNA3A initiates and maintains polycomb signatures across a chromatin domain encoding CXCL10 and CXCL9. PLoS Pathog 2013;9:e1003638.
-
(2013)
PLoS Pathog
, vol.9
-
-
Harth-Hertle, M.L.1
Scholz, B.A.2
Erhard, F.3
Glaser, L.V.4
Dolken, L.5
Zimmer, R.6
-
17
-
-
0037448353
-
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
-
Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.
-
(2003)
N Engl J Med
, vol.348
, pp. 203-213
-
-
Zhang, L.1
Conejo-Garcia, J.R.2
Katsaros, D.3
Gimotty, P.A.4
Massobrio, M.5
Regnani, G.6
-
18
-
-
69849107597
-
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments
-
Kryczek I, Banerjee M, Cheng P, Vatan L, SzeligaW, Wei S, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009;114:1141-9.
-
(2009)
Blood
, vol.114
, pp. 1141-1149
-
-
Kryczek, I.1
Banerjee, M.2
Cheng, P.3
Vatan, L.4
Szeliga, W.5
Wei, S.6
-
19
-
-
34247625135
-
Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells
-
Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007;21:1050-63.
-
(2007)
Genes Dev
, vol.21
, pp. 1050-1063
-
-
Tan, J.1
Yang, X.2
Zhuang, L.3
Jiang, X.4
Chen, W.5
Lee, P.L.6
-
20
-
-
34548238762
-
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control inmetastatic colorectal cancer patients treated with cetuximab
-
Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control inmetastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-7.
-
(2007)
J Clin Oncol
, vol.25
, pp. 3230-3237
-
-
Khambata-Ford, S.1
Garrett, C.R.2
Meropol, N.J.3
Basik, M.4
Harbison, C.T.5
Wu, S.6
-
21
-
-
84870573126
-
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
-
McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012;492:108-12.
-
(2012)
Nature
, vol.492
, pp. 108-112
-
-
McCabe, M.T.1
Ott, H.M.2
Ganji, G.3
Korenchuk, S.4
Thompson, C.5
Van Aller, G.S.6
-
22
-
-
35148867907
-
UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development
-
Agger K, Cloos PA, Christensen J, Pasini D, Rose S, Rappsilber J, et al. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature 2007;449:731-4.
-
(2007)
Nature
, vol.449
, pp. 731-734
-
-
Agger, K.1
Cloos, P.A.2
Christensen, J.3
Pasini, D.4
Rose, S.5
Rappsilber, J.6
-
23
-
-
84865120905
-
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response
-
Kruidenier L, Chung CW, Cheng Z, Liddle J, Che K, Joberty G, et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 2012;488:404-8.
-
(2012)
Nature
, vol.488
, pp. 404-408
-
-
Kruidenier, L.1
Chung, C.W.2
Cheng, Z.3
Liddle, J.4
Che, K.5
Joberty, G.6
-
24
-
-
0036274359
-
The fundamental role of epigenetic events in cancer
-
Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
-
(2002)
Nat Rev Genet
, vol.3
, pp. 415-428
-
-
Jones, P.A.1
Baylin, S.B.2
-
25
-
-
79960266611
-
EZH2 depletion blocks the proliferation of colon cancer cells
-
Fussbroich B, Wagener N, Macher-Goeppinger S, Benner A, Falth M, SultmannH, et al. EZH2 depletion blocks the proliferation of colon cancer cells. PLoS ONE 2011;6:e21651.
-
(2011)
PLoS ONE
, vol.6
-
-
Fussbroich, B.1
Wagener, N.2
Macher-Goeppinger, S.3
Benner, A.4
Falth, M.5
Sultmann, H.6
-
26
-
-
84937072873
-
Oncogenic CXCL10 signalling drives metastasis development and poor clinical outcome
-
Wightman SC, Uppal A, Pitroda SP, Ganai S, Burnette B, Stack M, et al. Oncogenic CXCL10 signalling drives metastasis development and poor clinical outcome. Br J Cancer 2015;113:327-35.
-
(2015)
Br J Cancer
, vol.113
, pp. 327-335
-
-
Wightman, S.C.1
Uppal, A.2
Pitroda, S.P.3
Ganai, S.4
Burnette, B.5
Stack, M.6
-
27
-
-
84869506748
-
The role of CXCR3 and CXCR4 in colorectal cancer metastasis
-
Murakami T, Kawada K, Iwamoto M, Akagami M, Hida K, Nakanishi Y, et al. The role of CXCR3 and CXCR4 in colorectal cancer metastasis. Int J Cancer 2013;132:276-87.
-
(2013)
Int J Cancer
, vol.132
, pp. 276-287
-
-
Murakami, T.1
Kawada, K.2
Iwamoto, M.3
Akagami, M.4
Hida, K.5
Nakanishi, Y.6
-
28
-
-
34248220334
-
CXCL10 promotes invasion-related properties in human colorectal carcinoma cells
-
Zipin-Roitman A, Meshel T, Sagi-Assif O, Shalmon B, Avivi C, Pfeffer RM, et al. CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res 2007;67:3396-405.
-
(2007)
Cancer Res
, vol.67
, pp. 3396-3405
-
-
Zipin-Roitman, A.1
Meshel, T.2
Sagi-Assif, O.3
Shalmon, B.4
Avivi, C.5
Pfeffer, R.M.6
-
29
-
-
33749319703
-
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
-
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4.
-
(2006)
Science
, vol.313
, pp. 1960-1964
-
-
Galon, J.1
Costes, A.2
Sanchez-Cabo, F.3
Kirilovsky, A.4
Mlecnik, B.5
Lagorce-Pages, C.6
-
30
-
-
79952093380
-
Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction
-
Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011;29: 610-8.
-
(2011)
J Clin Oncol
, vol.29
, pp. 610-618
-
-
Mlecnik, B.1
Tosolini, M.2
Kirilovsky, A.3
Berger, A.4
Bindea, G.5
Meatchi, T.6
-
31
-
-
29144514645
-
Effector memory T cells, early metastasis, and survival in colorectal cancer
-
Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353:2654-66.
-
(2005)
N Engl J Med
, vol.353
, pp. 2654-2666
-
-
Pages, F.1
Berger, A.2
Camus, M.3
Sanchez-Cabo, F.4
Costes, A.5
Molidor, R.6
-
32
-
-
33644856123
-
Epigenetic therapy of cancer: Past, present and future
-
Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006;5:37-50.
-
(2006)
Nat Rev Drug Discov
, vol.5
, pp. 37-50
-
-
Yoo, C.B.1
Jones, P.A.2
-
33
-
-
80052680422
-
The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML
-
Zhou J, Bi C, Cheong L-L, Mahara S, Liu S-C, Tay K-G, et al. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood 2011;118: 2830-9.
-
(2011)
Blood
, vol.118
, pp. 2830-2839
-
-
Zhou, J.1
Bi, C.2
Cheong, L.-L.3
Mahara, S.4
Liu, S.-C.5
Tay, K.-G.6
-
34
-
-
41149097574
-
Adoptive cell transfer: A clinical path to effective cancer immunotherapy
-
Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8:299-308.
-
(2008)
Nat Rev Cancer
, vol.8
, pp. 299-308
-
-
Rosenberg, S.A.1
Restifo, N.P.2
Yang, J.C.3
Morgan, R.A.4
Dudley, M.E.5
-
35
-
-
84860718270
-
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells
-
Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 2012;4:132ra53.
-
(2012)
Sci Transl Med
, vol.4
, pp. 132ra53
-
-
Scholler, J.1
Brady, T.L.2
Binder-Scholl, G.3
Hwang, W.T.4
Plesa, G.5
Hege, K.M.6
-
36
-
-
84858766182
-
The blockade of immune checkpoints in cancer immunotherapy
-
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature Rev Cancer 2012;12:252-64.
-
(2012)
Nature Rev Cancer
, vol.12
, pp. 252-264
-
-
Pardoll, D.M.1
|